Vibativ is owned by Cumberland Pharms.
Vibativ contains Telavancin Hydrochloride.
Vibativ has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Vibativ are:
Vibativ was authorised for market use on 11 September, 2009.
Vibativ is available in powder;intravenous dosage forms.
Vibativ can be used as method for treating bacterial infection.
The generics of Vibativ are possible to be released after 01 January, 2027.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US6635618||CUMBERLAND PHARMS||Glycopeptide phosphonate derivatives|| |
(7 months from now)
|US7531623||CUMBERLAND PHARMS||Hydrochloride salts of a glycopeptide phosphonate derivative|| |
(3 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US6858584||CUMBERLAND PHARMS||Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin|| |
(5 months ago)
Market Authorisation Date: 11 September, 2009
Treatment: Method for treating bacterial infection
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic